During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed quality of life and the future with CAR ...

Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...

The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

GSK has announced positive headline outcomes from a Phase III trial of Blenrep with bortezomib and dexamethasone for multiple ...

Don M. Benson, MD, PhD, has cared for patients at James Cancer Hospital in Ohio for 22 years, where he and his team see approximately 10,000 patient visits each year.

GSK reported positive results from its phase three ‘DREAMM-7’ trial on Thursday, highlighting a significant overall survival ...

High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.

The increase has been faster in women since 2000. The rising incidence of multiple myeloma (MM), particularly in relapsed and ...

GSK announced that belantamab mafodotin (Blenrep) plus bortezomib (Velcade) and dexamethasone improved overall survival in ...

In the end, all I could say is I have been there through sickness and your darkest times, and he didn’t say anything. I told ...

Co-owner of Burlington’s Finnigan’s Pub for more than 32 years was known for his work ethic, great attitude and remarkable ...

Multiple Myeloma, a cancer of the plasma cells in the bone marrow, is the third most common blood cancer in Europe. Despite recent advanced in treatment that has increased survival, it is still an ...